Contact Hours: 4
This educational activity is credited for 4 contact hours at completion of the activity.
Course Purpose
The purpose of this course is to provide healthcare providers with an overview of the distinctions between anticoagulant and antiplatelet medications, explain their respective roles in managing different conditions, and highlight the considerations for their safe and effective use.
Continuing Education Credit Designation
This educational activity is credited for 4 contact hours at completion of the activity.
Overview
In the realm of cardiovascular health, blood thinners, such as anticoagulants and antiplatelets, play a crucial role in patient care. Contrary to their name, these drugs do not actually “thin” the blood. Instead, they target different components within blood coagulation and platelet aggregation, two processes that contribute to the formation and growth of thrombi. While anticoagulants and antiplatelets have a similar overall effect, they have varying mechanisms of action, dosages, and interactions. Understanding these variances is essential for healthcare providers to tailor treatment and for patients to be well-informed about their therapy. This course aims to provide an overview of the distinctions between anticoagulant and antiplatelet medications, explain their respective roles in managing different conditions, and highlight the considerations for their safe and effective use.
Course Objectives
Upon completion of this course, the learner will be able to:
- • Review the pathophysiology of clot formation through the blood coagulation cascade and platelet aggregation.
- • Understand the indications for antiplatelet and anticoagulant use.
- • Review anticoagulants and antiplatelets, including mechanisms of action, medication types, doses, side effects, and reversal agents.
- • Review common laboratory findings for patients on antiplatelet and anticoagulants.
- • Identify herbal supplements that can increase the risk of bleeding.
- • Review patient and nursing considerations for antiplatelet and anticoagulant therapy.
Policy Statement
This activity has been planned and implemented in accordance with the policies of FastCEForLess.com.
Disclosures
Fast CE For Less, Inc and its authors have no disclosures. There is no commercial support.
To access Understanding the Difference Between Anticoagulants and Antiplatelets, purchase this course or a Full Access Pass.
If you already have an account, please sign in here.
To access Understanding the Difference Between Anticoagulants and Antiplatelets, purchase this course or a Full Access Pass.
If you already have an account, please sign in here.
Definitions
Activated Partial Thromboplastin Time (aPTT) | Measures the time it takes for a clot to form in a blood sample. |
Acute Coronary Syndrome (ACS) | A range of conditions related to sudden, reduced blood flow to the heart. |
Adenosine Diphosphate (ADP) | The source of energy for use and storage at the cellular level. |
Anti- Xa assay | A test that is designed to measure plasma heparin (unfractionated heparin [UH] and low–molecular weight heparin [LMWH]) levels and to monitor anticoagulant therapy. |
Anticoagulant | Medicines that prevent blood clots from forming in the bloodstream. |
Antiplatelet Therapy (DAPT) | Medications that prevent platelets from sticking together and forming blood clots. |
Antiplatelet | Medications that prevent blood clots from forming. |
Antithrombin III | A non-vitamin k–dependent protease that inhibits coagulation by neutralizing the enzymatic activity of thrombin. |
Atrial Fibrillation (AF) | A heart condition that causes an irregular and often abnormally fast heart rate. |
Blood Clot | Gel-like masses that manage bleeding. |
Blood Coagulation | An important process that prevents excessive bleeding when a blood vessel is injured. |
Blood Coagulation Cascade | Involves the activation of a series of clotting factors, which are proteins that participate in blood clotting. |
Blood Thinners | Medicines that help keep blood clots from easily forming, which keeps blood flowing smoothly through veins and arteries. |
Carotid Endarterectomy | A Surgery Performed to remove plaque buildup in the Common Carotid and Internal Carotid Arteries and improve blood flow. |
Chronic Pulmonary Hypertension | A type of high blood pressure that affects the arteries in the lungs and the right side of the heart. |
Common Pathway | The final pathway of blood clotting. |
Coronary Artery Bypass Grafting (CABG) | A surgical procedure that is done to treat a blockage or narrowing of one or more of the coronary arteries. |
Critical Limb Ischemia (CLI) | A severe stage of peripheral artery disease, in which there is a significant blockage in the blood flow to the arms, legs or feet. |
Direct Factor Xa Inhibitor | A type of anticoagulant that work by selectively and reversibly blocking the activity of clotting Factor Xa, preventing clot formation. |
Direct Oral Anticoagulant (DOAC) | Medications that function as direct inhibitors of thrombin or Factor Xa. |
Direct Thrombin Inhibitor | A class of anticoagulants, or blood thinners, which prevent blood clots by binding to thrombin and blocking its interaction with other proteins. |
Enzyme Cyclooxygenase-1 (COX-1) | An enzyme that produces prostaglandins (PGs) that play a role in homeostasis and physiological functions. |
Extrinsic Pathway | A coagulation pathway that is activated when tissue is damaged and is responsible for the initial phase of blood clotting. |
Factor IX | A protein produced naturally in the body that helps the blood form clots to stop bleeding. |
Factor VIII | An essential blood clotting protein that is deficient or defective in patients with classical hemophilia and Von Willebrand Syndrome. |
Factor X | A rare genetic blood disorder that causes the normal clotting process (coagulation) to take longer than normal. |
Factor Xa | Promotes coagulation by binding to Factor Va on membrane surfaces to form the prothrombinase complex. |
Factor XI | A plasma glycoprotein that acts in the contact phase of blood coagulation (the intrinsic pathway). |
Factor XII | Part of a group of proteins that act in a specific order to create a blood clot after an injury. |
Fibrin | A protein that helps form blood clots and participates in tissue repair. |
Fibrinogen | A protein produced in the liver that helps blood clot and stop bleeding. |
Fresh Frozen Plasma (FFP) | A blood product that is used to treat conditions that cause low blood clotting factors or low levels of other blood proteins. |
Glycoprotein IIb/IIIa Complex | A platelet transmembrane receptor that when activated causes platelets to aggregate by binding fibrinogen and Von Willebrand Factor. |
Glycoprotein IIb/IIIa Inhibitor | A class of drugs that prevent platelets from aggregating by blocking the binding of fibrinogen to the GP IIb/IIIa receptors on platelets. |
Heart Attack | Occurs when blood flow to the heart is suddenly blocked, which can damage or kill the heart muscle. |
Heparin-Induced Thrombocytopenia (HIT) | The development of thrombocytopenia , a severe complication that can occur in patients exposed to any form or amount of heparin products. |
International Normalized Ratio (INR) | A blood test that measures how long it takes for blood to clot. |
Intrinsic Pathway | Responds to spontaneous, internal damage of the vascular endothelium. |
Low Molecular Weight Heparin (LMWH) | A blood thinner derived from unfractionated heparin and is sometimes used to treat and prevent blood clots. |
Mechanical Heart Valve | A durable, artificial valve made of metal or carbon that replaces a damaged or diseased heart valve. |
Non-ST-Elevation Myocardial Infarction (NSTEMI) | A type of heart attack involving a partly blocked coronary artery that causes reduced blood flow. |
Percutaneous Coronary Intervention (PCI) | A non-surgical procedure that improves blood flow to the heart by treating blockages in the coronary arteries. |
Peripheral Artery Disease (PAD) | A common condition in which narrowed arteries reduce blood flow to the arms or legs. |
Phosphodiesterase Inhibitor | A class of drugs that block the action of phosphodiesterase enzymes in cells. |
Phosphodiesterase Type 3 | An intracellular enzyme that specifically hydrolyzes cAMP in myocardial and vascular tissue. |
Phosphodiesterase Type 5 | A vasodilating drug that works by blocking the degradative action of cGMP-specific phosphodiesterase. |
Platelet | Small, colorless cell fragments in our blood that form clots and stop or prevent bleeding. |
Platelet Aggregation | The process by which platelets adhere to each other to form a hemostatic plug at the site of an injury. |
Platelet Count | A blood test that measures how many platelets are in the blood |
Platelet Plug | An aggregation of platelets that forms during early stages of hemostasis to block blood vessel injuries. |
Post-Surgical Prophylaxis | Administering antibiotics before surgery to prevent infection. |
Prostacyclin Analog | Medications used to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs. |
Protease-Activated Receptor 1 (PAR1) Antagonist | A class of antiplatelet agents that inhibit thrombin-related platelet aggregation. |
Prothrombin Complex Concentrates (PCCs) | A hemostatic agent derived from human plasma that contains Factors II, VII, IX, And X, used to treat hemophilia. |
Prothrombin Time (PT) | A test that evaluates how long it takes for blood to clot. |
Pulmonary Embolism | A life-threatening condition caused by a blood clot that blocks an artery in the lung. |
Regurgitation | Occurs when a mixture of gastric juices and undigested food rises back up the esophagus and into the mouth. |
Serotonin | A chemical that carries messages between nerve cells and influences mood, sleep, digestion, nausea and more. |
ST-Elevation Myocardial Infarction (STEMI) | A type of acute coronary syndrome caused by complete occlusion of a coronary artery. |
Stroke | Occurs when the supply of blood to the brain is reduced or blocked completely, which prevents brain tissue from getting oxygen and nutrients. |
Thrombus | A blood clot that forms in a blood vessel and can block blood flow. |
Thrombocytopenia | A condition where the bone marrow does not make enough platelets, which help stop bleeding. |
Thromboplastin | Derived from cell membranes and is a mixture of both phospholipids and tissue factor, neither of which are enzymes. |
Thrombotic Thrombocytopenic Purpura (TTP) | A rare blood disorder in which thrombi (blood clots) form in small blood vessels throughout the body. |
Thromboxane A2 | A potent vasoconstrictor and platelet activator derived from arachidonic acid metabolism. |
Tissue Factor (TF) | Also called platelet tissue factor or coagulation factor iii, is a protein present in subendothelial tissue and leukocytes which plays a major role in coagulation and, in humans, is encoded by F3 Gene. |
Unfractionated Heparin | A fast-acting blood thinner that prevents clot formation and can be reversed by protamine. |
Unstable Angina | A type of chest pain that happens when your heart muscle does not get enough oxygen. |
Vitamin K Antagonist | Are a group of substances that reduce blood clotting by reducing the action of Vitamin K. |
In the realm of cardiovascular health, blood thinners, such as anticoagulants and antiplatelets, play a crucial role in patient care.1 Contrary to their name, these drugs do not actually “thin” the blood. Instead, they target different components within blood coagulation and platelet aggregation, two processes that contribute to the formation and growth of thrombi. Also known as blood clots, thrombi are solid masses formed as part of the body’s natural response to vascular injury, helping to prevent excessive bleeding.2 However, when blood clots form inappropriately within blood vessels, they can obstruct blood flow and cause serious complications. An even greater concern is the potential for these clots to dislodge and travel to vital organs, resulting in life-threatening events such as heart attacks, strokes, and pulmonary embolisms. Due to the significant risks linked with unregulated thrombus development, blood thinners are an essential therapeutic tool for managing patients with cardiovascular diseases, those who have undergone surgery, and individuals genetically predisposed to clot formation.
Not all blood thinners work in the same way. While anticoagulants and antiplatelets have a similar overall effect, such as reducing the risk of clot formation, they have varying mechanisms of action, dosages, and interactions. Understanding these variances is essential for healthcare providers to tailor treatment and for patients to be well-informed about their therapy. This course aims to clarify the distinctions between anticoagulant and antiplatelet medications, explain their respective roles in managing different conditions, and highlight the considerations for their safe and effective use.
To grasp the mechanisms of action for anticoagulants and antiplatelets, it is important to have a basic understanding of the blood coagulation cascade and platelet aggregation. The blood coagulation cascade is a complex series of events that helps stop bleeding after vascular injury.3 Numerous enzymatic reactions are involved that ultimately result in the materialization of a stable blood clot.
The coagulation cascade is split into three distinct pathways:
- The intrinsic pathway
- The extrinsic pathway
- The common pathway
The intrinsic pathway is triggered by blood vessel wall damage and involves several clotting factors already present in the bloodstream, including Factor XII, Factor XI, Factor IX, Factor VIII, and Factor X. The extrinsic pathway is triggered by external trauma to the blood vessel. It sees damaged tissues release tissue factor (TF), also known as thromboplastin, and is faster than the intrinsic pathway. The common pathway is where the intrinsic and extrinsic pathways converge. Key components in this process include the enzyme Factor Xa, which is critical for converting prothrombin into the active enzyme thrombin. Thrombin then converts fibrinogen (a soluble plasma protein) into fibrin (an insoluble fiber). Fibrin strands weave through the platelet plug (formed during platelet aggregation) to create a stable, insoluble mesh that is the final blood clot.
Platelet aggregation is the process by which the aforementioned platelet plug is formed.3 Platelets are small, smooth, disc-shaped blood cells found in blood plasma. In a vascular injury, these cells bind to the exposed extracellular matrix components in the damaged blood vessel wall. Following adhesion, platelets undergo a process known as activation. During activation, platelets change shape from smooth discs to irregular, spiky forms, increasing their surface area and enhancing their interaction capabilities. This shape change is accompanied by the release of granule contents, including clotting factors, adenosine diphosphate (ADP), thromboxane A2, and serotonin. These substances further activate and recruit additional platelets to the injury site. Adenosine diphosphate binds to the P2Y12 receptors on platelets, activating and promoting the glycoprotein IIb/IIIa complex, essential for platelet-to-platelet binding. Thromboxane A2, produced by the enzyme cyclooxygenase-1 (COX-1), is a lipid compound that stimulates platelets to clump together. Serotonin promotes vasoconstriction, which helps reduce blood flow to the site of injury and assists in stabilizing the forming clot. Activated platelets then begin the aggregation phase, where they bind to each other to create a platelet plug. This step is mediated by the glycoprotein IIb/IIIa receptors that become highly expressed on the surface of activated platelets. In healthy individuals without any underlying conditions, these processes are finely tuned to ensure blood clots form promptly at the injury site while being carefully controlled to prevent inappropriate clot formation.
Anticoagulants
Anticoagulants target various stages of the blood coagulation cascade and include unfractionated heparin, low molecular weight heparins (LMWHs), vitamin K antagonists, direct thrombin inhibitors, and direct Factor Xa inhibitors.4 Unfractionated heparin is the first anticoagulant ever used. Discovered in 1916, it enhances the activity of antithrombin III, a natural blood protein that inhibits blood clotting by blocking several clotting factors, particularly thrombin and factor Xa. Unfractionated heparin is injected, making it suitable for use in hospital settings where rapid onset is necessary. Low molecular weight heparins, such as enoxaparin and dalteparin, are derived from unfractionated heparin. However, they have a far more selective effect on factor Xa. This allows them to enhance the activity of antithrombin III with fewer effects on thrombin compared to unfractionated heparin. This results in a more predictable anticoagulant response. Low molecular weight heparins are often used for outpatient management of various thromboembolic conditions.
Vitamin K antagonists inhibit the action of vitamin K, a nutrient essential for synthesizing clotting factors II, VII, IX, and X. This effectively decreases the blood’s ability to clot, reducing the likelihood of clot formation.
Warfarin is a frequently used vitamin K antagonist. Approved by the FDA in 1954, warfarin has a long half-life of approximately 40 hours, resulting in a prolonged effect that makes it a suitable choice for long-term anticoagulation therapy.5
Direct thrombin inhibitors, such as dabigatran, represent the new generation of bioengineered drugs with a predetermined approach to anticoagulation. Approved by the FDA in 2010, dabigatran directly inhibits thrombin, preventing fibrin formation and subsequent clot stabilization.6 This class of anticoagulants does not require routine monitoring, making it a convenient option for many patients.
Direct factor Xa inhibitors, such as rivaroxaban (FDA approved in 2011) and apixaban (FDA approved in 2012), are another bioengineered drug that directly inhibits Factor Xa to reduce thrombin production.7,8 This, in turn, decreases fibrin formation and clotting. Like direct thrombin inhibitors, Xa inhibitors typically do not require regular monitoring.
Antiplatelets
Antiplatelets prevent blood clots by inhibiting platelets from activating, aggregating, or both. This reduces the stability of forming blood clots, thus reducing the risk of thrombotic events.9 Antiplatelets include aspirin, adenosine diphosphate (ADP) inhibitors, glycoprotein IIb/IIIa inhibitors, phosphodiesterase inhibitors, prostacyclin analogs, and PAR1 antagonists. Aspirin is one of the most widely used antiplatelet agents. Initially used as an anti-inflammatory agent, it was later seen to provide protection against heart attacks by irreversibly inhibiting COX-1, the enzyme that produces thromboxane A2. By limiting levels of thromboxane A2, aspirin reduces platelet clumping. As aspirin’s action is irreversible, its effects last as long as the lifespan of the platelet (7 – 10 days).
Adenosine diphosphate inhibitors, also called P2Y12 inhibitors, work by blocking 2Y12 receptors, a specific subtype of ADP receptors. Doing so prevents platelet-to-platelet binding and aggregation. Adenosine diphosphate inhibitors include clopidogrel, prasugrel, and ticagrelor. Clopidogrel, FDA-approved in 199710, is an oral P2Y12 inhibitor that irreversibly binds to the P2Y12 receptor on platelets. Despite its effectiveness, up to 10% of patients experience recurrent ischemic events within 12 months after acute coronary syndrome (ACS). Additionally, up to 34% of patients on clopidogrel continue to exhibit high on-treatment platelet reactivity.
Prasugrel is comparable to clopidogrel but has a more rapid and consistent activation. Approved by the FDA in 20099, it offers more potent and predictable antiplatelet effects. Ticagrelor is among a new generation of reversible P2Y12 inhibitors. Approved by the FDA in 2011, it is rapidly absorbed for faster onset and offset than clopidogrel.11
Glycoprotein IIb/IIIa inhibitors target the glycoprotein IIb/IIIa receptor on the surface of platelets, a key player in platelet clumping and binding to adhesive proteins.9 By blocking this receptor, these drugs stop platelets from sticking to each other and the vessel wall. Notable examples include eptifibatide and tirofiban. Eptifibatide is a cyclic peptide approved by the FDA in 1998.12 Eptifibatide binds reversibly to the glycoprotein IIb/IIIa receptor, effectively inhibiting platelet aggregation. It has a short half-life of approximately 2.5 hours and achieves steady-state platelet inhibition within 15 minutes of administration. This rapid onset makes eptifibatide especially useful in acute scenarios requiring swift platelet inhibition. Tirofiban, a non-peptide antagonist FDA-approved in 1998, also binds reversibly to the glycoprotein IIb/IIIa receptor. 13 It has a half-life of about 2 hours and reaches steady-state platelet inhibition in 20 – 40 minutes. Tirofiban is primarily used for managing acute coronary syndromes, where prompt platelet inhibition can prevent further cardiac events. After discontinuing either medication, platelet function recovers within 4 to 8 hours.
Phosphodiesterase inhibitors, such as dipyridamole and cilostazol, block the action of various phosphodiesterase enzymes, which break down cyclic adenosine monophosphate (cAMP)9. This increases cAMP levels in platelets, reducing activation and aggregation. Dipyridamole was originally developed as a coronary vasodilator but was later found to have antiplatelet effects by inhibiting phosphodiesterase types 3 and 5. Typically used with aspirin, dipyridamole is taken orally and has a half-life of about 10 – 12 hours. Platelet inhibition reaches a steady state in 4 – 7 days. Approved by the FDA in 1999, cilostazol is a selective phosphodiesterase 3A inhibitor also known for its vasodilatory effects.14 Cilostazol’s half-life is 11–13 hours, and platelet function recovery is approximately 12–16 hours after the medication is stopped.
Prostacyclin analogs, such as iloprost, mimic the effects of prostacyclin, a naturally occurring lipid compound that increases cAMP levels in platelets. Iloprost also serves as a vasodilator but can cause hypotension. However, it is metabolized rapidly, with an initial distribution half-life of 4 minutes and an elimination half-life of around 30 minutes.
Protease-activated receptor 1 (PAR1) antagonists block the PAR1 on platelets, inhibiting platelet activation and aggregation. Vorapaxar is an oral PAR1 antagonist used to reduce thrombotic events in patients with a medical history of such events. It has a half-life of 5 – 13 days and takes 4–8 weeks for platelet function to return to normal after discontinuation. Its prolonged effect limits its use in clinical settings.
Anticoagulants are used in cases where the clotting process must be broadly inhibited within blood vessels, such as in the veins or the heart. They are effective for treatment, long-term management, and as a prophylaxis.15 As a treatment, anticoagulants dissolve the existing clot, prevent its enlargement, and reduce the risk of further clot formation. The treatment approach usually involves higher doses of anticoagulants than prophylaxis. Long-term management involves careful monitoring and adjustments of the dosage to maintain therapeutic levels. This ongoing treatment helps prevent clot recurrence.
Anticoagulant prophylaxis refers to using blood thinners to prevent blood clot formation in patients who are at high risk but have not yet developed a clot. This approach is commonly employed after surgery, for stroke prevention, or in patients at high risk of a thromboembolic event, such as those with mechanical heart valves or a history of deep vein thrombosis (DVT). Prophylactic anticoagulation typically involves lower doses of anticoagulants compared to treatment doses.
Deep Vein Thrombosis (DVT)
Deep vein thrombosis (DVT) is blood clot development in a deep vein, most commonly in the legs.16 This condition occurs when blood flow is impaired, leading to clot formation in the veins. Deep vein thrombosis can be caused by prolonged immobility, such as during long flights or bed rest, trauma to the veins, or underlying medical conditions that increase blood clotting. The signs and symptoms of DVT can vary but typically include swelling in one leg, pain or tenderness that may start in the calf, and redness or warmth in the affected area. In some cases, the symptoms may be subtle, making the condition difficult to detect without medical evaluation. Swelling and pain often increase with physical activity or standing. The affected leg may also feel heavy or cramped. If left untreated, DVT can lead to a pulmonary embolism (PE). When treating DVT, heparin, LMWHs, or direct oral anticoagulants (DOACs) are often prescribed to prevent the clot from growing further. Typically, heparin is administered intravenously (IV) or subcutaneously (SC).17 The initial dose is normally 80-100 units/kg IV bolus followed by a continuous infusion of 18-20 units/kg/hour. LMWHs, such as enoxaparin, are administered SC. Typical dose is 1 mg/kg every 12 hours.18 The dosing may be adjusted based on renal function. Direct oral anticoagulants (DOACs) such as rivaroxaban or apixaban may also be given. Typically, the dosage of rivaroxaban may be 15 mg twice a day for the first 21 days, then 20 mg once daily.19 For apixaban, 10 mg is often taken twice a day for the initial week, then 5 mg twice daily.20 However, this may need to be adjusted based on factors such as renal function, age, weight, and the presence of interacting medications.
Pulmonary Embolism (PE)
Pulmonary Embolism (PE) is caused by a blood clot that has traveled to the blood vessels of the lungs, blocking a pulmonary artery or one of its branches. The blockage impairs blood flow to the lung tissue, reducing oxygen exchange and potentially causing damage to the lungs and heart. Pulmonary embolism can vary in severity, ranging from mild to life-threatening, and requires prompt medical attention to manage effectively. The symptoms of PE can be diverse but often include a sharp, sudden chest pain that worsens with deep breathing, breath shortness, and a cough that may produce blood-streaked sputum. Other symptoms may be present, such as irregular or rapid heartbeat, dizziness, lightheadedness, and fainting. These symptoms can develop suddenly and may occur after a period of immobility or recent surgery. If left untreated, PE can lead to severe complications and even be fatal. Blood flow obstruction damages lung tissue, leading to respiratory failure and cardiovascular collapse. Additionally, untreated PE can result in long-term complications such as chronic pulmonary hypertension, which can strain the heart and lead to persistent breathing difficulties and reduced exercise tolerance. Heparin and LMWHs are used to manage PE and prevent further clot formation. The dose of heparin to treat PE is usually the same as the dose for DVT treatment. It is administered IV with the dose being adjusted based on the patient’s health parameters.17 Alternatively, LMWH, such as enoxaparin may be administered at 1 mg/kg SC every 12 hours.18 While DOACs may be used, they normally follow initial treatment with parenteral anticoagulants, blood-thinning medications administered by routes other than oral.
Atrial Fibrillation (AF)
Atrial fibrillation (AF) is a common type of arrhythmia characterized by an irregular heartbeat originating from the atria, the heart’s upper chambers.22 This condition can be intermittent (paroxysmal), persistent, or permanent. Regardless of the type, AF disrupts the heart’s normal rhythm, potentially impairing its ability to pump blood efficiently. Signs and symptoms of AF can vary widely among individuals. Common symptoms include palpitations, which are sensations of a racing or irregular heartbeat, and fatigue due to the heart’s decreased efficiency in pumping blood. Other symptoms that may be present include dizziness, shortness of breath, and occasionally chest pain. Some individuals with AF may not experience noticeable symptoms and are diagnosed during a routine medical examination. If left unmanaged, AF can lead to several serious complications. One of the primary risks is stroke. The irregular heartbeats in AF can lead to blood clot formation in the atria, particularly in the left atrial appendage. These clots can then travel to the brain, causing a stroke. Anticoagulant medications, such as warfarin and DOACs, are given as prophylaxis to reduce the risk of such clots forming. Warfarin may be dosed at 2 – 5 mg daily.23 Direct oral anticoagulants may also be prescribed when a rapid onset of action is desirable.
Post-Surgical Prophylaxis
Post-surgical prophylaxis refers to the preventive measures to reduce the risk of thromboembolic events following surgical procedures.24 Complications may arise as a result of surgery, especially in surgeries involving the lower limbs or pelvis, which can lead to prolonged immobility and increase the likelihood of blood clots forming in the veins. Anticoagulants play a crucial role by directly targeting and reducing the risk of clot formation. Medications such as LMWHs and DOACs are generally preferred. Low molecular weight heparins such as enoxaparin are often started 12-24 hours after surgery with a typical dose of 40 mg SC once daily.18 Alternatively, DOACs such as rivaroxaban (10 mg once daily) or apixaban (2.5 mg twice daily) may be used postoperatively for extended prophylaxis.19,20
Mechanical Heart Valves
Mechanical heart valves are artificial devices constructed from durable materials such as carbon or titanium designed to mimic the function of natural valves.25 They replace damaged or diseased heart valves to ensure proper blood flows through the heart chambers and prevents regurgitation. Mechanical valves are often used in patients with severe valvular heart disease, where the native valve can no longer function effectively due to conditions such as stenosis (narrowing) or regurgitation (leakage). However, mechanical heart valves increase the risk of blood clot formation on or around the artificial valve. This is because the mechanical components of the valve can create turbulence in areas where blood clots are more likely to form. To mitigate this risk, anticoagulant therapy is prescribed to reduce the likelihood of clot formation. Warfarin is a commonly used anticoagulant for this purpose, and patients are typically dosed between 2 – 5 mg daily.23
Antiplatelets are used in cases where the primary issue is platelet aggregation rather than the broader clotting cascade. They are particularly effective for preventing arterial clots.9 Hence, they are commonly used in both primary and secondary prevention strategies for cardiovascular events, as well as in specific clinical scenarios where the risk of clot formation is high, such as acute coronary syndrome (ACS), peripheral artery disease (PAD), and postoperative management.
Primary Prevention
Antiplatelets are often prescribed for individuals at high risk of cardiovascular events but who have not yet experienced an event.9 This initiative-taking approach is known as primary prevention. It aims to prevent the initial occurrence of cardiovascular events in high-risk patients. Patients considered at high risk for cardiovascular events typically have one or more of the following risk factors: 26
- Diabetes
- Family history of cardiovascular disease
- Hyperlipidemia
- Hypertension
- Smoking
Chronic high blood pressure eventually damages the walls of arteries, making them more vulnerable to atherosclerosis and clot formation.
Elevated levels of LDL cholesterol also contribute to plaque formation. Diabetes is associated with increased platelet aggregation and a higher propensity for clot formation.
Smoking damages the endothelium (the inner lining of blood vessels) and promotes atherosclerosis. A family history of heart disease or stroke indicates a genetic predisposition to cardiovascular conditions, necessitating initiative-taking measures.
Low-dose aspirin (75-100 mg daily) is the most commonly used antiplatelet for primary prevention.27 Other antiplatelets, such as prasugrel, may be considered for patients who cannot tolerate aspirin or have specific risk profiles.
Secondary Prevention
For patients who have already had a cardiovascular event, such as a myocardial infarction (heart attack) or ischemic stroke, antiplatelet therapy is essential to prevent recurrence.9 These medications work by inhibiting platelet activation and aggregation, reducing the risk of new clot formation that could lead to subsequent events. Aspirin is often the first line of therapy due to its effectiveness, low cost, and well-established role in preventing recurrent cardiovascular events. The typical dose for secondary prevention is usually 81 mg per day. However, doses can increase to 325 mg depending on the patient’s risk profile and tolerance.27 The ADP inhibitor clopidogrel is used in patients who are either intolerant to aspirin or in combination with aspirin in dual antiplatelet therapy (DAPT). The standard dosage of is clopidogrel 75 mg once daily, and it is particularly useful in patients who have experienced a myocardial infarction, stroke, or have peripheral artery disease.28 Alternatively, ticagrelor, another ADP inhibitor, may be administered at 180 mg (loading dose), followed by a maintenance dose of 90 mg twice daily.29
Acute Coronary Syndrome (ACS)
Acute Coronary Syndrome (ACS) encompasses three serious conditions caused by a sudden drop or blockage of blood flow to the heart.30 These conditions include unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). Acute Coronary Syndrome typically results from atherosclerotic plaque rupture within a coronary artery, leading to clot formation and partial or complete block of blood flow to the heart muscle.The signs and symptoms of ACS can vary as they depend on the severity of the blockage. Common symptoms include:9
- Chest pain or discomfort, often described as pressure, squeezing, or burning sensation, usually in the center or left side of the chest that may radiate to the neck, jaw, shoulder, back, or arm.
- Cold sweat, often profuse and unexplained.
- Difficulty breathing or feeling winded, often accompanying chest pain.
- Fatigue.
- Lightheadedness or dizziness.
- Nausea and vomiting especially in women, elderly, and diabetic patients.
Antiplatelet therapy is a cornerstone in ACS management.9 Antiplatelet medications prevent platelets from clumping and forming clots, reducing the risk of further arterial blockage. Antiplatelets are used in both immediate and long-term treatment strategies. For immediate treatment, antiplatelets such as aspirin are used as soon as ACS is suspected. A typical dose is 162-325 mg of non-enteric-coated aspirin, chewed to ensure rapid absorption.27 P2Y12 inhibitors are often given in addition to aspirin to achieve rapid platelet inhibition. In high-risk patients or those undergoing percutaneous coronary intervention (PCI), glycoprotein IIb/IIIa inhibitors like eptifibatide or tirofiban may provide potent and immediate platelet inhibition. Following the acute phase, dual antiplatelet therapy (DAPT) is continued to prevent recurrent events. This typically involves 81 mg of aspirin daily with P2Y12 inhibitors for 12 months, with maintenance doses as follows: 75 mg clopidogrel daily, 90 mg twice ticagrelor daily, or 10 mg prasugrel daily (5 mg daily in patients weighing <60 kg or aged ≥75 years). The duration of this dual therapy may be adjusted based on the patient’s risk of bleeding and ischemic events.
Peripheral Artery Disease (PAD)
Peripheral Artery Disease (PAD) is a circulatory problem that causes reduced blood flow to the limbs, most commonly the legs.31 PAD is primarily caused by atherosclerosis, which narrows the arteries. Other causative factors include high blood pressure, high cholesterol, advanced age, obesity, smoking, and a family history of cardiovascular disease. Peripheral artery disease often goes undiagnosed because its symptoms can be mild or absent. When symptoms are noted, they usually include pain in the legs during walking or exercise that disappears after a few minutes of rest (intermittent claudication). If left untreated, PAD can lead to severe complications such as critical limb ischemia (CLI), where the blood flow is severely restricted, causing constant pain, sores, or infections. This can potentially lead to tissue death and amputation. Additionally, patients with PAD are at a higher risk of heart attacks and strokes. The choice of antiplatelet therapy may depend on individual patient factors, including tolerability and the presence of other medical conditions.9 Aspirin is often the first-line antiplatelet therapy for PAD, and the typical dose range is 81 – 325 mg once daily.
The P2Y12 inhibitor clopidogrel is another option and preferred for patients who are intolerant to aspirin or in combination with aspirin for enhanced antiplatelet effects. The usual dosage is 75 mg once daily.
Cilostazol is a phosphodiesterase III inhibitor that prevents platelet aggregation and causes vasodilation. It is particularly effective in improving walking distance in patients with intermittent claudication. However, cilostazol is not suitable for patients with heart failure due to its vasodilatory effects.
Postoperative Management
Cardiovascular surgeries like coronary artery bypass grafting (CABG), carotid endarterectomy, and percutaneous coronary interventions (PCI) are necessary for improving blood flow and reducing ischemic risk.32 However, they inherently disrupt the vascular endothelium, creating a pro-thrombotic environment. Antiplatelet therapy plays a crucial role in mitigating the risk by preventing platelet adhesion and aggregation at the surgical site. The initiation and duration of postoperative antiplatelet treatment depend on the type of surgery and the patient’s individual risk factors. For instance, aspirin is typically started within 6 hours postoperatively after coronary artery bypass grafting and continued indefinitely to prevent graft occlusion, such as when the graft becomes blocked or narrowed, resulting in reduced blood flow. In patients receiving percutaneous coronary interventions (PCI) with drug-eluting stents, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 is recommended for at least six months to prevent stent thrombosis.
While essential in preventing and treating thromboembolic events, blood thinners can cause several common side effects.33 The side effects include bleeding, gastrointestinal discomfort, possible decrease in appetite, weight loss, headaches, and dizziness. Bleeding is one of the most prevalent issues, with the severity ranging from minor nosebleeds and bruising to more serious gastrointestinal bleeding and intracranial hemorrhages. This also extends to prolonged bleeding from cuts and injuries as these medications prevent the normal clotting process, making it difficult for the body to stop bleeding once it starts. Even minor traumas can lead to significant blood loss. Gastrointestinal discomfort may occur as blood thinners can irritate the gastrointestinal lining or alter the normal balance of gut bacteria. Symptoms include nausea, indigestion, and diarrhea. Some blood thinners may also cause a decrease in appetite and weight loss as these medications can disrupt normal digestive processes and affect nutrient absorption. Some patients have also reported feeling dizziness and headaches. This may be due to the impact of blood thinners on blood pressure regulation or to changes in blood flow dynamics that affect the brain.
Warfarin, one of the most widely used anticoagulants, has a range of specific side effects.5 In addition to the general bleeding risks, patients on warfarin may also experience skin necrosis. In this rare but serious condition, skin tissue dies as a result of small blood clots forming in the skin’s blood vessels. Another notable side effect is the “purple toe syndrome,” where patients develop painful purple discoloration in their toes. It usually forms weeks to months after starting the medication. Warfarin also interacts with numerous drugs and dietary components, including, but not limited to vitamin K-rich foods, such as leafy green vegetables (spinach, kale), certain antibiotics, and antifungals.
Direct oral anticoagulants have their own side effects, including:4,7,9,10,11
- Aspirin, one of the most commonly used antiplatelet agents, can cause gastrointestinal irritation, and increase the risk of peptic ulcer disease.
- Chronic use of aspirin is associated with a higher risk of gastrointestinal bleeding, especially in patients with a history of ulcers or those taking other nonsteroidal anti-inflammatory drugs (NSAIDs).
- Clopidogrel can cause a condition known as thrombotic thrombocytopenic purpura (TTP), a rare but life-threatening disorder causing small blood clots to form throughout the body.
- Dabigatran can lead to dyspepsia (indigestion) and gastritis, which may be bothersome for some patients.
- Heparin can cause heparin-induced thrombocytopenia (HIT), a serious immune-mediated adverse reaction leading to a paradoxical increase in thrombotic events.
- Low molecular weight heparins can cause injection site reactions, such as pain, redness, and hematoma. Additionally, long-term use of these agents may lead to osteoporosis and increased fracture risk.
- Prasugrel and ticagrelor may cause dyspnea (shortness of breath) and, in some cases, bradyarrhythmia (slow heart rate).
Rivaroxaban and apixaban are known to cause liver enzyme abnormalities in some patients, necessitating periodic liver function tests.
Monitoring the efficacy and safety of blood thinners involves several key laboratory tests:
- Prothrombin Time (PT)
- International Normalized Ratio (INR)
- Activated Partial Thromboplastin Time (aPTT)
- Anti- Xa assay (heparin assay)
- Platelet count
Prothrombin time measures the time blood takes to clot, specifically assessing the extrinsic and common pathways of the coagulation cascade. Prothrombin time is crucial for assessing patients on vitamin K antagonists such as warfarin. The normal PT range is typically between 9 – 13.4 seconds.34
International Normalized Ratio (INR) is a standardized measure derived from the PT that adjusts for variations in test performance between different laboratories.35 For normal patients not on anticoagulation, the INR range is between 0.8 – 1.2. For patients on warfarin, the therapeutic INR range is between 2.0 and 3.0 for most conditions.34 For mechanical heart valves or other high-risk conditions, the INR may be targeted between 2.5 and 3.5. An INR above 3.0 indicates an increased bleeding risk due to excessive anticoagulation. An INR below 2.0 suggests inadequate anticoagulation and may require dose adjustment or additional medication.
Activated Partial Thromboplastin Time (aPTT) looks at the intrinsic and common coagulation pathways, measuring how well and quickly blood clots form.36 This test is primarily used for monitoring patients on heparin or LMWHs. The normal range for aPTT is approximately 25 to 36 seconds.37 For patients on heparin, the therapeutic range is typically 1.5 to 2.5 times the normal value or 37.5 to 87.5 seconds. Prolonged aPTT values beyond this range can indicate excessive anticoagulation, increasing the risk of bleeding. A shorter aPTT may suggest insufficient anticoagulation, potentially leading to thrombotic events.
An anti-Xa assay measures the activity of factor Xa.38 This test is specifically used to measure the activity of factor Xa in patients receiving LMWHs or direct factor Xa inhibitors. For patients on LMWH, therapeutic levels are typically 0.5 to 1.2 IU/mL. For direct factor Xa inhibitors, therapeutic ranges vary by medication and specific clinical scenarios, but generally aim to achieve levels that correlate with clinical efficacy and safety. High anti-factor Xa levels suggest over-anticoagulation, raising the risk of bleeding, while low levels indicate insufficient anticoagulation.
Platelet count reveals the number of platelets in the blood. While not directly related to anticoagulation, monitoring potential adverse effects such as thrombocytopenia (low platelet count) is important. The normal platelet count range is between 150,000 – 450,000 platelets per microliter of blood.39 A platelet count below 100,000 can be a side effect of certain anticoagulants like heparin and may increase the risk of bleeding or require discontinuation of the drug. Normal platelet count is generally positive, but sudden changes should be monitored to avoid potential complications.
Treatment Options for Abnormal Lab Findings
When laboratory findings indicate abnormal levels in patients on blood thinners, prompt and appropriate interventions are crucial to manage risks and ensure patient safety. For abnormal INR in patients on warfarin, treatment options depend on the degree of INR elevation and the presence of bleeding symptoms.4 For moderately elevated levels (4.5 to 10 without bleeding), oral vitamin K (1 – 2.5 mg) can be used. In cases of severe elevation or active bleeding, intravenous vitamin K (10 mg) may be necessary. In cases of life-threatening bleeding or exceedingly high INR (>10), prothrombin complex concentrates (PCCs) containing clotting factors II, VII, IX, and X may be administered to rapidly reverse the anticoagulation effect. When PCCs are unavailable, Fresh Frozen Plasma (FFP) may offer similar reversal effects. However, it requires time for thawing and administration. Elevated aPTT in patients on heparin requires reducing or discontinuing the heparin to normalize the test results. Continuous infusion allows for more precise adjustments. Protamine sulfate can be used for immediate reversal.40 An antidote for heparin, protamine sulfate reverses the anticoagulant effect. The dose is typically 1 mg of protamine per 100 units of heparin administered. Abnormal anti-factor Xa levels can be managed through dosage adjustments. In cases of severe bleeding or urgent procedures, specific reversal agents such as Andexanet alfa can be used on direct factor Xa inhibitors to reverse their effects.41 In cases of low platelet counts for patients on heparin, immediate discontinuation is required. Alternative anticoagulants like LMWHs or direct thrombin inhibitors may be used. In severe thrombocytopenia or bleeding cases, platelet transfusions may be considered to increase platelet levels and reduce the risk of further complications.42
Certain herbal supplements can interact with blood thinners, potentially increasing the risk of bleeding. These include: 43
- Chamomile
- Cranberry
- Dong qui
- Evening primrose
- Garlic
- Ginger
- Ginkgo biloba
- Ginseng
- Grapefruit
- Green tea
- Saw palmetto
- St. John’s Wort
Chamomile contains coumarins, and isolated incidents of enhanced bleeding in patients taking warfarin with chamomile have been reported.43
Cranberry is a fruit that contains compounds that can interact with blood thinners like warfarin. It may inhibit certain enzymes involved in drug metabolism, leading to an increased risk of bleeding by potentiating the effects of warfarin. Due to this potential interaction, caution is advised when consuming cranberry products while on anticoagulant therapy.
Dong quai is a traditional herb that contains coumarins and ferulic acid. These compounds can prolong prothrombin time and enhance bleeding risk, especially when taken with warfarin.
Evening primrose oil has gamma-linolenic acid, which can reduce thromboxane production and platelet aggregation. This can enhance the effects of blood thinners, increasing the risk of bleeding.
Garlic, a common culinary herb, is heralded for its cardiovascular benefits. It has been shown to inhibit platelet aggregation by enhancing fibrinolysis and reducing thromboxane synthesis. This action can potentiate the effects of anticoagulants and antiplatelets, raising the risk of bleeding.
Ginger is a root herb known for its anti-inflammatory and digestive benefits. Yet, it can also inhibit thromboxane synthesis and reduce platelet aggregation. When taken with blood thinners, it can increase bleeding risk, similar to garlic.
Ginkgo biloba is a supplement that originates from the leaves of a ginkgo tree. It is often used for cognitive enhancement and circulatory disorders. However, ginkgo inhibits platelet-activating factor, which can enhance blood thinners like warfarin and aspirin, leading to an increased bleeding risk.
Ginseng is a medicinal root that is widely used in traditional Asian medicine. Often used for its energy-boosting properties, ginseng can affect both platelet aggregation and blood clotting pathways. The interaction between ginseng and anticoagulants like warfarin can result in unpredictable bleeding complications.
Grapefruit can interact with warfarin by inhibiting cytochrome P450 enzymes (CYP3A4 and CYP2C9) involved in drug metabolism. The inhibition can increase warfarin levels in the blood, leading to an elevated risk of bleeding.
Green tea contains vitamin K and antiplatelet polyphenols. The vitamin K content may counteract the effects of anticoagulants, potentially reducing their effectiveness. Additionally, while green tea’s polyphenols can have antiplatelet effects, the presence of vitamin K may complicate its use in patients with blood thinners.
Saw palmetto is used for benign prostate hyperplasia and contains bioactive compounds that may interact with blood thinners. Despite a lack of direct antiplatelet activity, saw palmetto has been associated with increased bleeding risk when used with warfarin. The exact mechanism is unclear, but caution is advised, particularly during surgical procedures and when using blood-thinning medications. St. John’s Wort is a flowering plant widely used for depression. St. John’s Wort induces cytochrome P450 enzymes, which can accelerate the metabolism of blood thinners, potentially lessening their efficacy and intensifying the risk of thromboembolic events.
For patients on blood thinner therapy, certain considerations must be considered.44 The most important is adherence. Patients should follow the medication regimen precisely as directed by their healthcare provider. This means taking the correct dose at the right time. To support adherence, patients can use pill organizers, set reminders on their phones, or establish a routine that integrates medication-taking into their daily activities. It is also helpful for patients to keep a medication diary and to communicate openly with their healthcare team about any difficulties they encounter with their medication regimen, or potential side effects. Concurrently, certain lifestyle adjustments can help manage bleeding risk and ensure the effectiveness of the medication. Patients should adopt activities that minimize the risk of injury and bleeding. This includes avoiding high-impact sports and activities that could lead to falls or trauma. Patients should also be cautious with activities like gardening or using sharp objects and consider using protective gear. Dietary modifications are equally important. For those on anticoagulants like warfarin, it is crucial to monitor and possibly limit the intake of vitamin K-rich foods such as leafy green vegetables, as they can counteract the effects of the anticoagulant medications. Patients should aim for a consistent vitamin K intake rather than abrupt changes to their diet.
Regular monitoring and check-ups are also crucial for patients on blood thinners. Routine blood tests ensure that the desired level of blood anticoagulation is achieved without increasing the risk of bleeding. Regular check-ups also help healthcare providers adjust dosages based on the patient’s response and changes in health status. Keeping healthcare appointments also provides opportunities to discuss any new symptoms or side effects with healthcare providers, ensuring timely intervention and ongoing safety.
When managing patients on anticoagulant and antiplatelet therapy, nurses must be vigilant in monitoring for various complications to ensure safety and efficacy.45 One of the primary concerns is bleeding, as anticoagulants and antiplatelet increase the risk of both external and internal bleeding. Nurses should regularly check for signs such as excessive bruising, prolonged bleeding from cuts, bleeding gums, nosebleeds, blood in urine or stool, and symptoms of gastrointestinal bleeding like black or tarry stools and vomiting blood. Neurological symptoms, including severe headaches, altered mental status, or focal deficits, may indicate intracranial bleeding and require immediate attention.
Hemorrhage, a severe form of bleeding, demands urgent intervention. Nurses should be alert to signs such as hypotension, a rapid or weak pulse, pallor, cool, clammy skin, and any signs of shock.
While anticoagulants and antiplatelets are designed to reduce the risk of blood clots, inadequate dosing or missed doses can lead to thromboembolic events. Hence, nurses should monitor for symptoms of DVT and for signs of pulmonary embolism.
Adverse reactions to anticoagulants, such as allergic responses or other side effects like nausea, vomiting, dizziness, and changes in liver function, should also be closely observed. Drug interactions are another critical aspect, as anticoagulants can interact with a number of other medications, potentially reducing their effectiveness or increasing bleeding risks. Nurses should review the patient’s medication list and be aware of potential interactions and advise patients to inform them about any new medications or supplements they may be using.
Nurses must ensure regular testing of INR for patients on warfarin, aPTT for those on heparin, and anti-Xa assays for patients on LMWHs or oral anticoagulants. Not only are the tests vital for measuring the therapeutic effect of anticoagulants, but they also facilitate timely adjustments to dosages.
Patient education is vital for effective management of anticoagulant and antiplatelet therapy.46 Nurses should provide comprehensive information about the medication, including its purpose and dosage, and emphasize the importance of adherence to prescribed regimens. Patients should be informed about the side effects, especially increased bleeding risks, and they should be instructed to recognize signs of complications. Education should also cover the potential interactions with other medications, and dietary considerations, such as the impact of vitamin K on warfarin therapy.
Nurses should guide patients on safe medication storage, proper administration, and the importance of wearing medical alert identification. For those traveling, advice should include carrying an adequate medication supply and having an emergency care plan.
Ongoing follow-up appointments are essential to monitor anticoagulation status and adjust therapy as needed. Nurses should encourage patients to ask questions, express concerns, and maintain open communication with their healthcare providers to ensure optimal management of their anticoagulant therapy.
In cardiovascular care, understanding the distinct roles and mechanisms of anticoagulants and antiplatelets is essential for effective treatment and prevention of thrombotic events. While both classes of drugs aim to mitigate the risk of blood clots, they operate through different pathways. Each type of medication has its specific indications, benefits, and limitations. The choice between anticoagulants and antiplatelets depends on the underlying condition, patient risk factors, and therapeutic goals. Understanding these differences enhances the ability of healthcare providers to provide effective treatment and improve patient outcomes. For patients, being informed about their medication can enable them to participate in their care and make informed decisions about their health. Routine laboratory monitoring remains a cornerstone in managing patients on anticoagulant therapy. These tests help adjust dosages to ensure maximum therapeutic effect with minimal risks. For optimal management, patients must diligently follow their prescribed medication regimen, make informed lifestyle adjustments, and openly communicate with their healthcare providers. Healthcare professionals also play a central role in ensuring comprehensive monitoring, providing education on managing side effects and drug interactions, and making necessary adjustments to treatment plans. Ultimately, through thoughtful application and vigilant oversight, abnormal clotting can be effectively controlled, significantly improving cardiovascular health and overall quality of life.
- Medline Plus. (2019). Blood Thinners. Medlineplus.gov; National Library of Medicine. https://medlineplus.gov/bloodthinners.htm
- Govindarajan, V., Rakesh, V., Reifman, J., & Mitrophanov, A. Y. (2016). Computational Study of Thrombus Formation and Clotting Factor Effects under Venous Flow Conditions. Biophysical Journal, 110(8), 1869-1885. https://doi.org/10.1016/j.bpj.2016.03.010
- Al-Koussa, H., AlZaim, I., & El-Sabban, M. E. (2022). Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders. Journal of Clinical Medicine, 11(16). https://doi.org/10.3390/jcm11164932
- Heestermans, M., Poenou, G., Hamzeh-Cognasse, H., Cognasse, F., & Bertoletti, L. (2022). Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells, 11(20). https://doi.org/10.3390/cells11203214
- Coumadin (warfarin sodium) tablets Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf
- PRADAXA (dabigatran etexilate) capsules, for oral use label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022512s039lbl.pdf
- XARELTO (rivaroxaban) Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859s000lbl.pdf
- ELIQUIS (apixaban) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
- Jourdi, G., Lordkipanidzé, M., Philippe, A., Bachelot-Loza, C., & Gaussem, P. (2021). Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. International Journal of Molecular Sciences, 22(23). https://doi.org/10.3390/ijms222313079
- PLAVIX (clopidogrel bisulfate) tablets, for oral use label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020839s070lbl.pdf
- BRILINTA (ticagrelor) tablets, for oral use label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022433s020lbl.pdf
- Integrilin (eptifibatide) injection label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf
- AGGRASTAT (tirofiban hydrochloride) injection, for intravenous use label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020912s024,020913s022lbl.pdf
- PLETAL (cilostazol) tablets, for oral use Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020863s024lbl.pdf
- Anticoagulant Therapy – an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/medicine-and-dentistry/anticoagulant-therapy
- Alexander, P., Visagan, S., Issa, R., Gorantla, V. R., & Thomas, S. E. (2021). Current Trends in the Duration of Anticoagulant Therapy for Venous Thromboembolism: A Systematic Review. Cureus, 13(10). https://doi.org/10.7759/cureus.18992
- Medscape. (2019, September 28). Heparin dosing, indications, interactions, adverse effects, and more. Medscape.com. https://reference.medscape.com/drug/calciparine-monoparin-heparin-342169
- Medscape. (2019, September 28). Lovenox (enoxaparin) dosing, indications, interactions, adverse effects, and more. Medscape.com. https://reference.medscape.com/drug/lovenox-enoxaparin-342174
- Medscape. (2019, October 14). Xarelto (rivaroxaban) dosing, indications, interactions, adverse effects, and more. Medscape.com. https://reference.medscape.com/drug/xarelto-rivaroxaban-999670
- Medscape. (2019, December 9). Eliquis (apixaban) dosing, indications, interactions, adverse effects, and more. Medscape.com. https://reference.medscape.com/drug/eliquis-apixaban-999805
- Naoum, J. J. (2024). Anticoagulation Management Post Pulmonary Embolism. Methodist DeBakey Cardiovascular Journal, 20(3), 27-35. https://doi.org/10.14797/mdcvj.1338
- Tai, W. (2023). Atrial Fibrillation: A Common Cause of Stroke. Delaware Journal of Public Health, 9(3), 12-15. https://doi.org/10.32481/djph.2023.08.004
- Coumadin, Jantoven (warfarin) dosing, indications, interactions, adverse effects, and more. (n.d.). Reference.medscape.com. https://reference.medscape.com/drug/coumadin-jantoven-warfarin-342182
- Tun, H. N., Kyaw, M. T., Rafflenbeul, E., & Suástegui, X. L. (2022). Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis. European Cardiology Review, 17. https://doi.org/10.15420/ecr.2021.55
- Langenaeken, T., Vanoppen, A., Janssens, F., Tanghe, L., Verbrugghe, P., Rega, F., & Meuris, B. (2023). DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives. Journal of Clinical Medicine, 12(15). https://doi.org/10.3390/jcm12154984
- World Health Organization. (2021, June 11). Cardiovascular diseases (CVDs). World Health Organization; World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- Medscape. (n.d.). Bayer Buffered Aspirin, Vazalore (aspirin) dosing, indications, interactions, adverse effects, and more. Reference.medscape.com. https://reference.medscape.com/drug/bayer-vazalore-aspirin-343279
- Plavix (clopidogrel) dosing, indications, interactions, adverse effects, and more. (n.d.). Reference.medscape.com. https://reference.medscape.com/drug/plavix-clopidogrel-342141
- Brilinta (ticagrelor) dosing, indications, interactions, adverse effects, and more. (n.d.). Reference.medscape.com. https://reference.medscape.com/drug/brilinta-ticagrelor-999674
- Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2008). Acute coronary syndromes. Lancet (London, England), 399(10332), 1347-1358. https://doi.org/10.1016/S0140-6736(21)02391-6
- Soyoye, D. O., Abiodun, O. O., Ikem, R. T., Kolawole, B. A., & Akintomide, A. O. (2021). Diabetes and peripheral artery disease: A review. World Journal of Diabetes, 12(6), 827-838. https://doi.org/10.4239/wjd.v12.i6.827
- Mahmood, H., Siddique, I., & McKechnie, A. (2019). Antiplatelet drugs: A review of pharmacology and the perioperative management of patients in oral and maxillofacial surgery. Annals of The Royal College of Surgeons of England, 102(1), 9-13. https://doi.org/10.1308/rcsann.2019.0154
- Harter, K., Levine, M., & Henderson, S. O. (2014). Anticoagulation Drug Therapy: A Review. Western Journal of Emergency Medicine, 16(1), 11-17. https://doi.org/10.5811/westjem.2014.12.22933
- Prothrombin Time (PT) and International Normalized Ratio (INR) – Hunterdon Medical Center. (2024). Testcatalog.org. https://hmc.testcatalog.org/show/PT-1
- International Normalized Ratio – an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/nursing-and-health-professions/international-normalized-ratio
- Activated Partial Thromboplastin Time – an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/engineering/activated-partial-thromboplastin-time
- Activated Partial Thromboplastin Time (PTT) – Hunterdon Medical Center. (2024). Testcatalog.org. https://hmc.testcatalog.org/show/PTT-1
- Heparin Anti-Xa – Hunterdon Medical Center. (2024). Testcatalog.org. https://hmc.testcatalog.org/show/HPXA
- Platelet Count – Hunterdon Medical Center. (2024). Testcatalog.org. https://hmc.testcatalog.org/show/PLT-1
- Protamine Sulfate – an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/neuroscience/protamine-sulfate
- Momin, J. H., Candidate, P., & Hughes, G. J. (2019). Andexanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants. Pharmacy and Therapeutics, 44(9), 530. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705484/
- Thrombocyte Transfusion – an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/medicine-and-dentistry/thrombocyte-transfusion
- Abebe, W. (2019). Review of herbal medications with the potential to cause bleeding: Dental implications, and risk prediction and prevention avenues. The EPMA Journal, 10(1), 51-64. https://doi.org/10.1007/s13167-018-0158-2
- Blood Thinner Pills: Your Guide to Using Them Safely. (n.d.). Www.ahrq.gov. https://www.ahrq.gov/patients-consumers/diagnosis-treatment/treatments/btpills/btpills.html
- Palomo Lara, J. C., March-Cerdà, J. C., Ponce-Blandón, J. A., Pabón-Carrasco, M., & Jiménez-Picón, N. (2024). Effectiveness and Health Outcomes of Collaborative Nurse Prescribing for Patients Anticoagulated with Antivitamin K in Primary Care: A Study Protocol. Healthcare, 12(3). https://doi.org/10.3390/healthcare12030347
- Hawes, E. M. (2018). Patient Education on Oral Anticoagulation. Pharmacy: Journal of Pharmacy Education and Practice, 6(2). https://doi.org/10.3390/pharmacy6020034
To access Understanding the Difference Between Anticoagulants and Antiplatelets, purchase this course or a Full Access Pass.
If you already have an account, please sign in here.
To access Understanding the Difference Between Anticoagulants and Antiplatelets, purchase this course or a Full Access Pass.
If you already have an account, please sign in here.